S&P 500   3,894.70 (+2.19%)
DOW   31,589.17 (+2.12%)
QQQ   321.81 (+2.44%)
AAPL   125.94 (+3.86%)
MSFT   236.38 (+1.72%)
FB   261.43 (+1.48%)
GOOGL   2,059.08 (+1.84%)
TSLA   716.61 (+6.09%)
AMZN   3,123.16 (+0.98%)
NVDA   548.21 (-0.07%)
BABA   239.59 (+0.77%)
CGC   35.21 (+7.51%)
GE   13.22 (+5.42%)
MU   94.25 (+2.97%)
NIO   49.70 (+8.56%)
AMD   85.45 (+1.11%)
T   28.28 (+1.40%)
F   12.01 (+2.65%)
ACB   11.36 (+7.98%)
DIS   195.96 (+3.66%)
BA   225.66 (+6.44%)
NFLX   551.50 (+2.35%)
BAC   35.70 (+2.85%)
S&P 500   3,894.70 (+2.19%)
DOW   31,589.17 (+2.12%)
QQQ   321.81 (+2.44%)
AAPL   125.94 (+3.86%)
MSFT   236.38 (+1.72%)
FB   261.43 (+1.48%)
GOOGL   2,059.08 (+1.84%)
TSLA   716.61 (+6.09%)
AMZN   3,123.16 (+0.98%)
NVDA   548.21 (-0.07%)
BABA   239.59 (+0.77%)
CGC   35.21 (+7.51%)
GE   13.22 (+5.42%)
MU   94.25 (+2.97%)
NIO   49.70 (+8.56%)
AMD   85.45 (+1.11%)
T   28.28 (+1.40%)
F   12.01 (+2.65%)
ACB   11.36 (+7.98%)
DIS   195.96 (+3.66%)
BA   225.66 (+6.44%)
NFLX   551.50 (+2.35%)
BAC   35.70 (+2.85%)
S&P 500   3,894.70 (+2.19%)
DOW   31,589.17 (+2.12%)
QQQ   321.81 (+2.44%)
AAPL   125.94 (+3.86%)
MSFT   236.38 (+1.72%)
FB   261.43 (+1.48%)
GOOGL   2,059.08 (+1.84%)
TSLA   716.61 (+6.09%)
AMZN   3,123.16 (+0.98%)
NVDA   548.21 (-0.07%)
BABA   239.59 (+0.77%)
CGC   35.21 (+7.51%)
GE   13.22 (+5.42%)
MU   94.25 (+2.97%)
NIO   49.70 (+8.56%)
AMD   85.45 (+1.11%)
T   28.28 (+1.40%)
F   12.01 (+2.65%)
ACB   11.36 (+7.98%)
DIS   195.96 (+3.66%)
BA   225.66 (+6.44%)
NFLX   551.50 (+2.35%)
BAC   35.70 (+2.85%)
S&P 500   3,894.70 (+2.19%)
DOW   31,589.17 (+2.12%)
QQQ   321.81 (+2.44%)
AAPL   125.94 (+3.86%)
MSFT   236.38 (+1.72%)
FB   261.43 (+1.48%)
GOOGL   2,059.08 (+1.84%)
TSLA   716.61 (+6.09%)
AMZN   3,123.16 (+0.98%)
NVDA   548.21 (-0.07%)
BABA   239.59 (+0.77%)
CGC   35.21 (+7.51%)
GE   13.22 (+5.42%)
MU   94.25 (+2.97%)
NIO   49.70 (+8.56%)
AMD   85.45 (+1.11%)
T   28.28 (+1.40%)
F   12.01 (+2.65%)
ACB   11.36 (+7.98%)
DIS   195.96 (+3.66%)
BA   225.66 (+6.44%)
NFLX   551.50 (+2.35%)
BAC   35.70 (+2.85%)
Log in
NYSE:ENZ

Enzo Biochem Stock Forecast, Price & News

$2.98
+0.06 (+2.05 %)
(As of 03/1/2021 11:09 AM ET)
Add
Compare
Today's Range
$2.95
Now: $2.98
$3.01
50-Day Range
$2.61
MA: $3.07
$3.46
52-Week Range
$1.56
Now: $2.98
$4.85
Volume4,858 shs
Average Volume349,066 shs
Market Capitalization$142.73 million
P/E RatioN/A
Dividend YieldN/A
Beta0.89
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 34 patient service centers in New York and New Jersey; and a free-standing Â'STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.
Enzo Biochem logo

Headlines

Enzo Biochem’s CEO urged to resign by top investor
February 27, 2021 |  seekingalpha.com
Is Enzo Biochem, Inc. (NYSE:ENZ) Popular Amongst Insiders?
January 30, 2021 |  finance.yahoo.com
Enzo Biochem and Tenneco See Activist Action
January 22, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone212-583-0100
Employees408
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$76.02 million
Book Value$1.22 per share

Profitability

Net Income$-28,520,000.00

Miscellaneous

Market Cap$142.73 million
Next Earnings Date3/4/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

0.67 out of 5 stars

Medical Sector

1252nd out of 1,962 stocks

Medical Laboratories Industry

26th out of 39 stocks

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
$2.98
+0.06 (+2.05 %)
(As of 03/1/2021 11:09 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ENZ News and Ratings via Email

Sign-up to receive the latest news and ratings for ENZ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Enzo Biochem (NYSE:ENZ) Frequently Asked Questions

What stocks does MarketBeat like better than Enzo Biochem?

Wall Street analysts have given Enzo Biochem a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Enzo Biochem wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Enzo Biochem's next earnings date?

Enzo Biochem is scheduled to release its next quarterly earnings announcement on Thursday, March 4th 2021.
View our earnings forecast for Enzo Biochem
.

How were Enzo Biochem's earnings last quarter?

Enzo Biochem, Inc. (NYSE:ENZ) issued its quarterly earnings results on Wednesday, December, 9th. The medical research company reported $0.01 EPS for the quarter. The medical research company earned $28.66 million during the quarter. Enzo Biochem had a negative net margin of 24.36% and a negative trailing twelve-month return on equity of 27.05%.
View Enzo Biochem's earnings history
.

How has Enzo Biochem's stock price been impacted by COVID-19?

Enzo Biochem's stock was trading at $2.86 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ENZ shares have increased by 3.1% and is now trading at $2.95.
View which stocks have been most impacted by COVID-19
.

Who are Enzo Biochem's key executives?

Enzo Biochem's management team includes the following people:
  • Dr. Elazar Rabbani, Co-Founder, Chairman, CEO & Sec. (Age 78, Pay $1.31M)
  • Mr. Barry W. Weiner, Founder, Treasurer & Pres (Age 71, Pay $1.09M)
  • Mr. David A. Bench, CFO & Principal Accounting Officer
  • Ms. Kara Cannon, Chief Commercial Officer (Age 53, Pay $293.05k)
  • Dr. Dieter Schapfel, Chief Medical Director of Enzo Clinical Labs (Age 58, Pay $403.53k)
  • Mr. Bruce A. Dey, VP of Sales & Marketing - Enzo Clinical Labs (Age 63)

Who are some of Enzo Biochem's key competitors?

What other stocks do shareholders of Enzo Biochem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enzo Biochem investors own include OneLife Technologies (OLMM), Gilead Sciences (GILD), OPKO Health (OPK), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Pfizer (PFE), Advanced Micro Devices (AMD), Amarin (AMRN) and Micron Technology (MU).

What is Enzo Biochem's stock symbol?

Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ."

Who are Enzo Biochem's major shareholders?

Enzo Biochem's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.84%), Renaissance Technologies LLC (7.43%), Evermore Global Advisors LLC (5.44%), Dimensional Fund Advisors LP (3.56%), Ariel Investments LLC (1.82%) and Northern Trust Corp (1.07%). Company insiders that own Enzo Biochem stock include Discovery Fund Lp Harbert, Harbert Management Corp and Peter J Iv Clemens.
View institutional ownership trends for Enzo Biochem
.

Which institutional investors are selling Enzo Biochem stock?

ENZ stock was sold by a variety of institutional investors in the last quarter, including Evermore Global Advisors LLC, Dimensional Fund Advisors LP, Wells Fargo & Company MN, Corrado Advisors LLC, Renaissance Technologies LLC, Northern Trust Corp, GSA Capital Partners LLP, and Los Angeles Capital Management LLC.
View insider buying and selling activity for Enzo Biochem
or view top insider-selling stocks.

Which institutional investors are buying Enzo Biochem stock?

ENZ stock was bought by a variety of institutional investors in the last quarter, including VIEX Capital Advisors LLC, BlackRock Inc., JPMorgan Chase & Co., Corsair Capital Management L.P., Ariel Investments LLC, Clear Harbor Asset Management LLC, Squarepoint Ops LLC, and Strs Ohio. Company insiders that have bought Enzo Biochem stock in the last two years include Discovery Fund Lp Harbert, Harbert Management Corp, and Peter J Iv Clemens.
View insider buying and selling activity for Enzo Biochem
or or view top insider-buying stocks.

How do I buy shares of Enzo Biochem?

Shares of ENZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enzo Biochem's stock price today?

One share of ENZ stock can currently be purchased for approximately $2.95.

How much money does Enzo Biochem make?

Enzo Biochem has a market capitalization of $141.29 million and generates $76.02 million in revenue each year.

How many employees does Enzo Biochem have?

Enzo Biochem employs 408 workers across the globe.

What is Enzo Biochem's official website?

The official website for Enzo Biochem is www.enzo.com.

Where are Enzo Biochem's headquarters?

Enzo Biochem is headquartered at 527 Madison Ave., New York NY, 10022.

How can I contact Enzo Biochem?

Enzo Biochem's mailing address is 527 Madison Ave., New York NY, 10022. The medical research company can be reached via phone at 212-583-0100.


This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.